Gene · 7030
Papers3,398
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,398
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Flufenamic acid inhibits pyroptosis in ischemic flaps via the AMPK-TRPML1-Calcineurin signaling pathway. | Burns Trauma | 2025 | 40655077 | PubTator, text mining | PubMed |
| Non-clear cell renal cell carcinoma: unpacking a messy term. | Clin Adv Hematol Oncol | 2025 | 40590879 | PubTator, text mining | PubMed |
| Clinicopathological Features and Prognostic Factors of Renal Cell Carcinoma in Young Patients Under 45 Years: A Single-Center Retrospective Study. | Cancer Manag Res | 2025 | 40584225 | PubTator, text mining | PubMed |
| Diagnostic accuracy of TRIM63 RNA-ISH in MiTF-rearranged renal cell carcinomas: Results from a 331-tumor validation cohort. | Hum Pathol | 2025 | 40578488 | PubTator, text mining | PubMed |
| Birt-Hogg-Dubé syndrome - a rare genetic disorder complicated by pneumothorax: A case report. | World J Clin Cases | 2025 | 40574922 | PubTator, text mining | PubMed |
| Longitudinally extensive transverse myelitis after pembrolizumab and lenvatinib therapy for a rare subtype of renal cell carcinoma: A case report. | Oncol Lett | 2025 | 40535096 | PubTator, text mining | PubMed |
| Case Report: Extrarenal TFE3 fusion-related renal cell carcinoma. | Front Oncol | 2025 | 40510143 | PubTator, text mining | PubMed |
| Tumorous cholesterol biosynthesis curtails anti-tumor immunity by preventing MTOR-TFEB-mediated lysosomal degradation of CD274/PD-L1. | Autophagy | 2025 | 40509568 | PubTator, text mining | PubMed |
| TFE3-rearranged renal cell carcinoma - Expanding the histomorphological spectrum. | Indian J Pathol Microbiol | 2025 | 40485553 | PubTator, text mining | PubMed |
| An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying SFPQ-TFE3 driven translocation RCC. | iScience | 2025 | 40463960 | PubTator, text mining | PubMed |
| Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases. | Histopathology | 2025 | 40462401 | PubTator, text mining | PubMed |
| Clinical features and therapeutic experiences of renal cancer related to Xp11.2 translocation/TFE3 gene fusion: A case series of 18 patients. | Pathol Res Pract | 2025 | 40446477 | PubTator, text mining | PubMed |
| TFE3-rearranged PEComa-like neoplasm of the kidney with carcinoma-like morphology and rapid progression: a case report. | World J Surg Oncol | 2025 | 40442772 | PubTator, text mining | PubMed |
| Intraspinal ASPSCR1::TFE3 rearranged tumor with nerve differentiation. | Brain Tumor Pathol | 2025 | 40419820 | PubTator, text mining | PubMed |
| Morphologic and immunophenotypic characterization of conventional FLCN-mutated tumors (FMT) compared to a series of 8 non-conventional FMT. | Hum Pathol | 2025 | 40412633 | PubTator, text mining | PubMed |
| TFE3-mediated lysosomal biogenesis and homeostasis alleviates arsenic-induced lysosomal and immune dysfunction in macrophages. | Ecotoxicol Environ Saf | 2025 | 40409189 | PubTator, text mining | PubMed |
| Unlocking diagnostic potential: A retrospective analysis of GPNMB immunohistochemistry in nearly 1000 surgical pathology specimens. | Hum Pathol | 2025 | 40389121 | PubTator, text mining | PubMed |
| The Critical Role of FLCN, TFE3, and TFEB in Bioenergetic and Nutrient Sensing, Renal Cancer Tumorigenesis and Metabolic Health. | Eur Urol | 2025 | 40382298 | PubTator, text mining | PubMed |
| Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry. | Hum Pathol | 2025 | 40381702 | PubTator, text mining | PubMed |
| TFE3/TFEB altered renal cell carcinomas in end-stage renal disease setting: A single institution clinicopathological study of 4 cases. | Hum Pathol | 2025 | 40339759 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7030/papers?page=12